Latest Breaking News On - Hepatocellular carcinoma - Page 10 : comparemela.com

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

France generalSan franciscoUnited statesChristelle huguetIpsen euronextEuropean medicines agencyOno pharmaceutical coAmerican cancer societyTakeda pharmaceutical company limitedAmerican society of clinical oncology genitourinary symposiumWorld cancer research fund internationalHead of researchEuropean unionBristol myers squibbTakeda pharmaceutical companyTranslational research unit at georges pompidou hospital

Fostrox/Lenvatinib Combination Displays Efficacy, Tolerability in Pretreated HCC

Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.

Comunidad autonoma de catalunaUnited kingdomSouth koreaMaria reigHospital provincial clinic de barcelonaHepatocellular carcinomaMiv 818

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

Riccardo lencioniDepartment of surgeryCritical area pathologyDruvalumab and bevacizumab plus taceHepatocellular carcinomaGastrointestinal cancerGi cancerAsco giTransarterial chemoembolizationPhase 3 emerald 1 trial2024 gastrointestinal cancers symposiumUniversità di pisa

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs TACE in liver cancer eligible for embolization

EMERALD-1 is first global Phase III trial to show improved clinical outcome for systemic therapy in combination with TACE in this setting .

United statesUnited kingdomSan franciscoSouth koreaSusan galbraithBruno sangroDaiichi sankyoNational cancer instituteWorld health organizationBiosciences incMerck co incLiver unitUniversidad de navarraExecutive vice presidentResponse rateBlinded independent central review

ASCO GI 2024: Golden Biotech s Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients

ASCO GI 2024: Golden Biotech s Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesT ai peiPrnewswire golden biotechnology corpGolden biotechnology corporation the companyAmerican society of clinical oncologyGolden biotechnology corpBiotechnology corpPancreatic cancerCancers symposiumGolden biotechTrial registration numberAmerican societyClinical oncologyClinically meaningful goalsFor pancreatic cancer